Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens

Filippo Pietrantonio, Federica Perrone, Pamela Biondani, Claudia Maggi, Andrea Lampis, Claudia Bertan, Filippo Venturini, Luca Tondulli, Daris Ferrari, Vincenzo Ricci, Federica Villa, Gloria Barone, Nadia Bianco, Antonio Ghidini, Ilaria Bossi, Giuseppe Fanetti, Maria Di Bartolomeo, Filippo De Braud

Research output: Contribution to journalArticlepeer-review


Background. Few data are available outlining outcomes of panitumumab in advanced colorectal cancer patients benefiting from prior cetuximab-based regimens. Patients and methods. Thirty patients with KRAS wild type metastatic colorectal cancer with clinical benefit from prior cetuximab-based regimens between May 2004 and October 2011 were reviewed at nine Italian Institutions. Inclusion key criteria included interruption of cetuximab for reasons other than progressive disease. Patients were classified according to prior regimens (0 or =1), prior response or stabilization, surgery of metastases, and Kohne prognostic score. At the time of subsequent progression, patients were treated with single agent panitumumab until progressive disease, unacceptable toxicity, or consent withdrawal. Results. Panitumumab obtained 67% disease control rate and 30% objective response rate, with median PFS of 4.2 and median OS of 9.6 mo. Patients with BRAF/NRAS/PI3KCA and KRAS (by mutant enriched technique) wild-type tumors had the best chance of response to panitumumab. Conclusions. Single agent panitumumab provided significant clinical benefit in heavily pretreated patients without acquired resistance to prior cetuximab-based regimens.

Original languageEnglish
Pages (from-to)1098-1103
Number of pages6
JournalCancer Biology and Therapy
Issue number12
Publication statusPublished - Dec 2013


  • Cetuximab
  • Colorectal cancer
  • KRAS
  • Panitumumab
  • Rechallenge

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens'. Together they form a unique fingerprint.

Cite this